الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 62 |  |  |
| | | from | 62 | | |
Abstract
In 2022, World Health Organization (WHO) reports that the main cause of death worldwide is related to cardiovascular diseases (CVDs). Furthermore, in 2019, 32% of all fatalities worldwide were attributable to CVDs and killed approximately 17.9 million individuals. In Egypt CVD related deaths made up 46.6% of all fatalities in 2017. Appropriate actions in detecting individuals at risk, monitoring, and early intervention are crucial.
Alopecia areata (AA) and Androgenic alopecia (AGA) have been connected to several comorbid conditions including CVDs. Cardiac Troponin I (cTnI) is more specific in predicting cardiac-related diseases and could be used as a screening test for individuals at risk. To our knowledge, there is a limited number of studies and regular follow up on these patients for CVD risk in Egypt.
This study aimed at measuring cTnI biomarkers and comparing them in AA and AGA and Healthy Controls (HCs) subjects attending the outpatient dermatology clinic of the Alexandria University Main Hospital in Alexandria, Egypt to assess their CVD risk. Relationships between Troponin with sex, age, and smoking were likewise evaluated.
To accomplish this aim, a cross-sectional study was done on a total of 90 subjects who were above 40 yrs comprised of 30 subjects with sex-matched AA, AGA, and HCs.
All subjects’ blood sample was taken to the laboratory for cTnI testing. Data were collected from August 2021 to July 2022. The laboratory results were recorded for each subject.
The current study revealed the duration of disease in androgenic alopecia patients ranged from 3 months to 20.00 years with a median of 4.00 years, while in alopecia areata patients it ranged from 2 weeks to 7 years with a median of 1.84 years. The duration of disease in androgenic alopecia patients was statistically significantly longer than in alopecia areata patients (p<.001).
In this study, cTnI median levels in all subjects were observed to be within the normal range, even though AA subjects had significantly higher (p =0.047) compared to AGA subjects and HCs groups(p<.001).
The androgenic alopecia group cTnI showed a statistically significant higher level than the healthy group (p=.015).
Nevertheless, males and females among all studied groups showed no statistically significant difference in the level of cTnI.
Regarding smoking, the study observed no statistically significant difference in cTnI levels in smokers and non-smokers among the three groups